hs-CRP Test · Blood

Your standard cholesterol panel might look perfect, and you could still be at serious risk for a heart attack. That blind spot is inflammation, a slow-burning process inside your artery walls that standard blood tests do not capture. hs-CRP (high-sensitivity C-reactive protein) is the single best blood test for measuring that hidden fire. A 2025 scientific statement from the American College of Cardiology now recommends that everyone get this test, not just people who already have heart disease.

The reason is straightforward: the predictive power of hs-CRP for heart attacks, strokes, and cardiovascular death is comparable to blood pressure and cholesterol. In a study of nearly 450,000 adults without known heart disease, those with hs-CRP above 3 mg/L had a 34% higher risk of major cardiovascular events, a 61% higher risk of dying from heart disease, and a 54% higher risk of dying from any cause compared to those with levels below 1 mg/L.

What hs-CRP Tells You

CRP is a protein your liver produces whenever your body detects inflammation, infection, or tissue damage. It is part of your innate immune system, the body's first line of defense. During a severe infection, CRP can spike by a thousandfold. But hs-CRP is not looking for those dramatic spikes. The "high-sensitivity" designation means this version of the test can detect very low concentrations, down to 0.3 mg/L, which lets it pick up the subtle, chronic inflammation that smolders inside artery walls for years before a heart attack or stroke.

CRP does more than just signal inflammation. It binds to oxidized LDL cholesterol (the damaged form of "bad" cholesterol) and is found inside the fatty plaques that clog arteries. Research suggests it may actively promote the growth of those plaques by encouraging immune cells to stick to artery walls and by impairing the function of the blood vessel lining. This means hs-CRP is both a messenger reporting on inflammation and a participant in the damage.

Heart Disease Risk

The cardiovascular evidence for hs-CRP is extensive. A meta-analysis covering more than 160,000 people without prior heart disease and 1.3 million person-years of follow-up found that each standard-deviation increase in hs-CRP was associated with a 37% higher risk of coronary heart disease and a 55% higher risk of cardiovascular death. These effect sizes were comparable to or stronger than those for total cholesterol, HDL cholesterol, and blood pressure.

The risk does not plateau. Across the full range of hs-CRP values, higher levels mean higher risk in a dose-response pattern. A pooled analysis of three large statin trials, including over 31,000 patients, showed that people in the highest quarter of hs-CRP had roughly 2.5 times the risk of dying from cardiovascular causes compared to those in the lowest quarter, even after accounting for cholesterol levels and other standard risk factors.

What matters most is not a single snapshot but a sustained pattern. A study following more than 10,000 adults over 15 years found that people whose hs-CRP remained elevated at 3 mg/L or above across two measurements taken six years apart had a 51% higher risk of coronary heart disease, a 70% higher risk of stroke, a 60% higher risk of heart failure, and a 52% higher risk of dying from any cause.

Stroke Risk

A 30-year follow-up of nearly 28,000 initially healthy women found that those in the highest fifth of hs-CRP had a 56% higher risk of ischemic stroke (the type caused by a clot) compared to the lowest fifth. A separate study of over 90,000 Chinese adults confirmed a dose-response relationship: hs-CRP between 1 and 3 mg/L raised ischemic stroke risk by 17%, and levels above 3 mg/L raised it by 33%.

The direction your hs-CRP is trending may matter as much as the absolute number. In a UK Biobank analysis of nearly 15,000 participants, people whose hs-CRP rose over time had a 65% higher risk of ischemic stroke, and those who remained persistently elevated had a 74% higher risk of any stroke and a 91% higher risk of hemorrhagic stroke (the type caused by a bleed).

Type 2 Diabetes

Chronic low-grade inflammation and insulin resistance are tightly linked, and hs-CRP captures this connection. A meta-analysis of 36 studies involving more than 125,000 participants found that people with the highest hs-CRP levels were about 77% more likely to develop type 2 diabetes compared to those with the lowest levels, even after adjusting for BMI and other metabolic risk factors.

A Norwegian population study of over 8,000 adults followed for seven years found that those in the highest third of hs-CRP had 73% higher odds of developing diabetes compared to the lowest third. This association held after adjusting for obesity and high blood pressure, suggesting that inflammation contributes to diabetes risk independently of body weight.

Cancer Associations

The link between chronic inflammation and cancer is well established biologically, and hs-CRP data increasingly support it. A large Japanese study tracking over 3,600 cancer cases for a median of 15.6 years found that people in the highest quarter of CRP had a 28% higher overall cancer risk compared to the lowest quarter. The associations were strongest for colorectal, lung, breast, biliary tract, and kidney cancers.

A meta-analysis pooling data from over 100 studies confirmed positive associations between CRP and several specific cancers, with the strongest link seen for lung cancer, where higher CRP roughly doubled the risk. In a Danish study of over 10,400 people followed for up to 16 years, baseline CRP above 3 mg/L was associated with a 30% higher risk of developing any cancer and an 80% higher risk of early death in people who were subsequently diagnosed with localized cancer.

Reference Ranges

Body weight is the single strongest factor that shifts your baseline hs-CRP. Obesity increases the odds of an elevated reading by 3 to 13 times compared to normal weight, so interpreting your result without considering your BMI can be misleading.

These tiers come from the CDC/AHA consensus, based on data from over 19,000 people across 12 populations and more than 22,000 U.S. adults. They apply across sex and ethnicity, though average levels differ somewhat: African Americans tend to have the highest median values, followed by Hispanics and South Asians, with East Asians having the lowest. These differences appear largely driven by socioenvironmental factors like BMI and smoking rather than genetics. Your lab may use slightly different cutpoints, so the most meaningful comparison is always your own number over time, measured at the same lab.

Tracking Your Trend

A single hs-CRP reading is useful, but a trend over time is far more powerful. The within-person variability of hs-CRP is significant: a large real-world study of over 472,000 people found a coefficient of variation of about 160%, meaning your number can swing considerably from one draw to the next. About 32% of people with an initially elevated reading were reclassified as normal on repeat testing less than three weeks later.

Despite this short-term variability, the long-term tracking stability of hs-CRP is comparable to LDL cholesterol and better than blood pressure, with studies showing intraclass correlations of 0.54 to 0.77. This means that over months and years, your underlying trend is reliable even if individual readings bounce around. The six-year sustained-elevation data make this point clearly: people whose hs-CRP stayed high across two measurements years apart faced dramatically higher risks than those with a single elevated reading.

Get a baseline reading when you are feeling well, with no recent illness. If it comes back above 3 mg/L, repeat it in 2 to 3 weeks to confirm. Once you have a reliable baseline, retest every 6 to 12 months, or sooner if you are making significant lifestyle changes and want to see whether they are working. If you start a statin or anti-inflammatory therapy, recheck in 3 to 6 months to see whether your inflammatory risk is dropping alongside your cholesterol.

When Results Can Be Misleading

Any recent infection, surgery, or significant tissue injury can spike hs-CRP well above 10 mg/L for days to weeks. Even a mild upper respiratory infection can elevate your reading enough to push you into a higher risk category that does not reflect your true baseline. If your result is above 10 mg/L, guidelines recommend waiting 2 to 3 weeks and retesting, then using the lower of the two values for risk assessment.

Vigorous exercise causes a short-lived rise in hs-CRP proportional to the intensity and degree of muscle damage. This acute bump fades within a few days and is less pronounced in well-trained individuals. Avoid intense workouts for 24 to 48 hours before your blood draw to get a cleaner reading.

Oral estrogen (including birth control pills and some forms of hormone replacement therapy) raises hs-CRP, but topical estrogen does not. If you are on oral estrogen, your reading may appear higher than your true vascular inflammatory risk. Obesity is the most persistent confounder: adipose tissue produces inflammatory signals that chronically elevate hs-CRP, so a high reading in someone with a high BMI partly reflects excess body fat rather than vascular inflammation specifically.

PCSK9 inhibitors (a class of cholesterol-lowering injections) cause a small but consistent increase in hs-CRP of about 0.11 mg/L, despite dramatically lowering LDL cholesterol. This rise is modest and should not be mistaken for worsening cardiovascular risk.